The House Energy and Commerce Committee yesterday approved several bills designed to enhance prescription drug competition.
Details: This includes the CREATES Act, which received bipartisan buy-in after relatively minor changes were made to the original version.
- That bill would allow generics manufacturers to sue brand-name drugmakers for access to the samples they need for approval, although the new version offers more protections to brands.
- The committee also passed a bill that makes it illegal for branded companies to pay generic companies to stay off the market.
The big picture: CREATES is expected to save the federal government $3.9 billion over 10 years, a fraction of the $100 billion spent on Medicare's prescription drug benefit alone in 2017.
- But Congress has thus far struggled to do much of anything, and the push to reduce drug prices has to start somewhere.
Go deeper: The drug pricing debate is stuck in the past
